4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity
London, UK, 9 April 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired the Contract, Manufacturing and Controls (CMC) team and site in Alachua, Florida, from Beacon Therapeutics (Beacon).
- London, UK, 9 April 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired the Contract, Manufacturing and Controls (CMC) team and site in Alachua, Florida, from Beacon Therapeutics (Beacon).
- The transaction brings an operational good manufacturing practice (GMP) facility, process and analytical development capabilities, and additional experts to the Ascend team.
- This key acquisition brings Ascend its first US manufacturing site, a huge milestone for the Company.
- The facility is highly synergistic to a growing global network of Ascend sites that has been built via critical acquisitions.